Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
Public ClinicalTrials.gov record NCT00093145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin® As First-Line Therapy of Advanced HER-2 Positive Breast Cancer
Study identification
- NCT ID
- NCT00093145
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Interventions
- Albumin-bound paclitaxel Drug
- Carboplatin Drug
- Herceptin® Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2004
- Primary completion
- Sep 30, 2008
- Completion
- Sep 30, 2008
- Last update posted
- Nov 24, 2019
2004 – 2008
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Breastlink Med Group | Long Beach | California | 90806 | — |
| Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center | Stamford | Connecticut | 06902 | — |
| Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | — |
| Lombardi Cancer Center Georgetown University Hospital | Washington D.C. | District of Columbia | 2007 | — |
| Florida Cancer Institute | Hudson | Florida | 34667 | — |
| Gulf Coast Oncology Associates | St. Petersburg | Florida | 33705 | — |
| Palm Beach Cancer Institute | West Palm Beach | Florida | 33401 | — |
| Gerogia Cancer Specialist | Atlanta | Georgia | 30341 | — |
| Maine Center for Cancer Medicine and Blood Disorders | Scarborough | Maine | 04074 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| University of Pittsburgh Medical Center Magee Womens Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Southwest Regional Cancer Center | Austin | Texas | 78705 | — |
| Swedish Medical Center Cancer Institute Research | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00093145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 24, 2019 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00093145 live on ClinicalTrials.gov.